Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: A phase II trial of the University of Chicago phase II consortium

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 6, 2008, Pages 553-556

  Kindler, Hedy Lee ^a   Aklilu, Mebea ^a   Nattam, Sreenivasa ^b   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b Fort Wayne Medical Education Program   (United States)

Author keywords

Arsenic trioxide; Pancreatic cancer; Phase II trial

Indexed keywords

ARSENIC TRIOXIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE LIVER LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LEUKOPENIA; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ARSENICALS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDES; PANCREATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58149260050     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318178e4cd     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Murray T, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Burris HA, Moore MJ, Andersen J 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of Arsenic Trioxide. Cancer Res. 2002;62:3893-3903.
4. 3) in the treatment of acute promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
5. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
6. Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol. 2002;42:5-24.
7. Wang ZY. Arsenic compounds as anticancer agents. Ca Chemother Pharmacol. 2001;48(suppl 1):S72-S76.
8. Li X, Ding X, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. Anticancer Res. 2002;22:2205-22013.
9. Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas. 2003;27:174-179.
10. 3) in patients with solid tumors. Proc Am Soc Clin Oncol. 1999;18:228.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
13. Kaplan E. and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Klapdor R, Fenner C. Irinotecan (Campto): effiacay as third/forth-line therapy in advanced pancreatic cancer. Anticancer Res. 2000;20:5209-5212.
15. Oettle H, Arnold D, Esser M, et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000;11:635-638.
16. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003;88:1180-1184.
17. Jacobs AD, Burris HA, Rivkin S, et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North American multi-center study. Proc Am Soc Clin Oncol. 2004;23:315.